Carey T E, Takahashi T, Resnick L A, Oettgen H F, Old L J
Proc Natl Acad Sci U S A. 1976 Sep;73(9):3278-82. doi: 10.1073/pnas.73.9.3278.
We studied how frequently patients with malignant melanoma have specific antibody to cell surface antigens of cultured autologous melanoma cells as demonstrated by mixed hemadsorption assays. Of 35 patients studied over periods ranging from 1 to 36 months with Stage II, III, and IV disease, two showed consistent and high titered reactivity against autologous melanoma cells, two showed less consistent and intermediate reactivity, seven showed sporatic, low titered reactivity, and the remainder were consistently negative. A detailed analysis was carried out with the sera of one patient with sufficiently high titer against autologous melanoma cells. By direct tests and by absorption analysis with a variety of melanoma and nonmelanoma cell lines which included autologous fibroblasts, the antigen could not be demonstrated on any cell type other than the autologous melanoma.
我们通过混合血细胞吸附试验研究了恶性黑色素瘤患者针对培养的自体黑色素瘤细胞表面抗原产生特异性抗体的频率。在对35例处于II、III和IV期疾病的患者进行了为期1至36个月的研究中,2例对自体黑色素瘤细胞表现出持续且高滴度的反应性,2例表现出反应性较低且不一致,7例表现出散在、低滴度的反应性,其余患者始终为阴性。对一名针对自体黑色素瘤细胞具有足够高滴度的患者血清进行了详细分析。通过直接检测以及用包括自体成纤维细胞在内的多种黑色素瘤和非黑色素瘤细胞系进行吸收分析,除自体黑色素瘤外,在任何细胞类型上均未检测到该抗原。